Globeflex Capital’s CytomX Therapeutics CTMX Stock Holding History

Globeflex Capital’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-69,435	Closed	-$185K	–	491
2022 Q1	$185K	Hold	69,435	–	–	0.04%	349
2021 Q4	$301K	Hold	69,435	–	–	0.06%	322
2021 Q3	$353K	Sell	69,435 -46,333	-40%	-$248K	0.08%	277
2021 Q2	$733K	Buy	115,768 +121	+0.1%	+$942	0.13%	242
2021 Q1	$894K	Buy	115,647 +46,212	+67%	+$366K	0.16%	205
2020 Q4	$455K	Hold	69,435	–	–	0.1%	304
2020 Q3	$462K	Hold	69,435	–	–	0.12%	263
2020 Q2	$578K	Buy	+69,435	New	+$645K	0.15%	241
2016 Q2	–	Sell	-59,000	Closed	-$761K	–	465
2016 Q1	$761K	Buy	+59,000	New	+$819K	0.2%	171

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Globeflex Capital's CTMX Position: Q2 2022 in Review

Globeflex Capital sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 69,435 shares — an estimated $185K sold.

Globeflex Capital first reported a position in CTMX in Q1 2016 and held it in 9 quarters. The position peaked at $894K in Q1 2021. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

Globeflex Capital reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
Globeflex Capital sold 69,435 CytomX Therapeutics shares in Q2 2022, an estimated $185K.
Globeflex Capital first reported a position in CytomX Therapeutics in Q1 2016 and held it in 9 quarters.
Globeflex Capital's CytomX Therapeutics position peaked at $894K in Q1 2021.
98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Globeflex Capital's 13F filing for Q2 2022, filed 15 Aug 2022.